Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AtriCure, Inc. - Common Stock (NQ:ATRC)

27.30 +0.39 (+1.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook ↗
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding... 
Via MarketBeat
News headline image
AtriCure (ATRC) Q1 2026 Earnings Transcript ↗
AtriCure (ATRC) Q1 2026 Earnings Transcript 
Via The Motley Fool
AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone ↗
Via Chartmill
News headline image
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions. 
Via The Motley Fool
Topics Regulatory Compliance
AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
AtriCure Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 12, 2025 ↗
 
Via Benzinga
News headline image
Expert Outlook: AtriCure Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? ↗
This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns. 
Via The Motley Fool
Topics Derivatives Regulatory Compliance
News headline image
AtriCure (ATRC) Q4 2025 Earnings Call Transcript ↗
AtriCure (ATRC) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Deep Dive Into AtriCure Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares? ↗
This cardiac device maker focused on atrial fibrillation saw a notable insider sale following a year of flat share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
AtriCure (ATRC) Q3 2025 Earnings Call Transcript ↗
AtriCure (ATRC) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
AtriCure Inc (NASDAQ:ATRC) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Outlook ↗
AtriCure's Q3 2025 earnings beat expectations with a narrowed loss and strong revenue growth. The medical device firm also raised its full-year financial outlook. 
Via Chartmill
Topics Earnings
News headline image
AtriCure (ATRC) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
AtriCure (ATRC) Q2 Revenue Jumps 17% ↗
Via The Motley Fool
News headline image
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
14 Analysts Assess AtriCure: What You Need To Know ↗
 
Via Benzinga
News headline image
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
11 Analysts Have This To Say About AtriCure ↗
 
Via Benzinga
News headline image
Apple To $183? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.